Voyager Therapeutics, INC 8-K filings

Voyager Therapeutics announced positive GLP toxicology data for its Alzheimer's gene therapy candidate, VY1706, demonstrating a favorable tolerability profile and effective CNS delivery in non-human primates.

Voyager Therapeutics announced an increase in authorized shares following its 2026 Annual Meeting of Stockholders.

Voyager Therapeutics announced its investigational tau gene therapy, VY1706, has received FDA clearance for an Investigational New Drug application, paving the way for a clinical trial in early Alzheimer's disease.

Voyager Therapeutics announced first quarter 2026 financial results, highlighting pipeline progress with IND-enabling studies completed for VY1706 and NBIB-233, and a cash runway extending into 2028.

Voyager Therapeutics announced the resignation of its Chief Financial Officer, Nathan Jorgensen, effective May 8, 2026, and the appointment of Robin Swartz as principal financial officer and treasurer.

Voyager Therapeutics announced the resignation of its Chief Medical Officer, Toby Ferguson, effective February 20, 2026, with CEO Alfred W. Sandrock, Jr. assuming interim responsibilities.

Voyager Therapeutics, Inc. provides an investor presentation and letter to stockholders outlining its strategic priorities and anticipated milestones for 2026, focusing on tau-targeted therapies and novel delivery platforms.

Voyager Therapeutics announced third quarter 2025 financial results, highlighted by progress in its tau-targeting programs and the introduction of its NeuroShuttle delivery platform, while maintaining cash runway into 2028.

Voyager Therapeutics presented its next-generation NeuroShuttle platform and robust CNS pipeline, emphasizing its strategy to mitigate neuro risk and strong financial position.

Voyager Therapeutics announced second quarter 2025 financial results, reporting a net loss of $33.4 million, but extended its cash runway into 2028 and expanded its Alzheimer's disease pipeline.

Voyager Therapeutics, Inc. announced that its stockholders approved the 2025 Stock Incentive Plan, the Amended and Restated 2015 Employee Stock Purchase Plan, and re-elected Class I directors at its annual meeting on June 3, 2025.

Voyager Therapeutics announced its first quarter 2025 financial results, highlighting advancements in its Alzheimer's disease programs and a strong cash position extending into mid-2027.

Voyager Therapeutics announces positive results from its tau silencing gene therapy program and extends its cash runway into mid-2027, driven by advancements in its Alzheimer's disease and partnered programs.

Voyager Therapeutics is shifting its focus in its ALS program, leading to a delay in the planned IND filing for VY9323.

Voyager Therapeutics announced positive third quarter 2024 financial results, highlighted by increased collaboration revenue and advancements in their gene therapy pipeline.

Voyager Therapeutics grants Novartis an exclusive license for a capsid, receiving a $15 million upfront payment and potential milestones totaling up to $305 million.

Voyager Therapeutics announced positive second quarter 2024 financial results, highlighted by increased collaboration revenue and advancements in their gene therapy programs.

Voyager Therapeutics has appointed Nathan Jorgensen as its new Chief Financial Officer, effective no later than July 8, 2024.

Voyager Therapeutics held its annual meeting on June 5, 2024, where stockholders elected three Class III directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent auditor.

Voyager Therapeutics has dosed the first participants in a Phase 1a trial for its anti-tau antibody, VY-TAU01, aimed at treating Alzheimer's disease.

Voyager Therapeutics reports first quarter 2024 financial results, highlighted by IND clearance for their anti-tau antibody and advancements in gene therapy programs.

Voyager Therapeutics' Chief Financial Officer, Peter P. Pfreundschuh, is stepping down, with Robin Swartz appointed as the new principal financial officer, effective April 12, 2024.

Voyager Therapeutics has appointed Toby Ferguson, M.D., Ph.D., as its new Chief Medical Officer, effective March 25, 2024.

Voyager Therapeutics announced positive fourth quarter and full year 2023 financial results, highlighted by significant collaboration revenue and advancements in their gene therapy programs.